专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140066370A1 Polypeptide Conjugate 审中-公开
标题翻译：多肽缀合物
公开(公告)号：US20140066370A1
公开(公告)日：2014-03-06
申请号：US13511201
申请日：2010-11-23
申请人： Behrouz Bruce Forood , Soumitra S. Ghosh , James L. Trevaskis , Chengzao Sun , Odile Esther Levy , Lawrence J. D'Souza , Christopher J. Soares
发明人： Behrouz Bruce Forood , Soumitra S. Ghosh , James L. Trevaskis , Chengzao Sun , Odile Esther Levy , Lawrence J. D'Souza , Christopher J. Soares
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , A61K47/54 , A61K47/542 , A61K47/554 , A61K47/60 , A61K47/64 , A61K47/643 , C07K14/575 , C07K14/57563 , C07K14/585
摘要： The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.
摘要翻译：本公开提供多肽缀合物具有多种改善的药理学和药代动力学性质及其在治疗各种疾病和病症如糖尿病和/或肥胖症中的用途。

2. 发明申请

US20120071401A1 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS 审中-公开
标题翻译：用于雌激素缺乏型乳腺的AMYLIN激动剂化合物
公开(公告)号：US20120071401A1
公开(公告)日：2012-03-22
申请号：US13263070
申请日：2010-04-09
申请人： Jonathan David Roth , James L. Trevaskis , David G. Parkes
发明人： Jonathan David Roth , James L. Trevaskis , David G. Parkes
IPC分类号： A61K38/17 , A61P5/24 , A61P3/04 , A61K38/38
CPC分类号： A61K38/22 , A61K38/2264 , A61K38/23 , C07K14/575 , A61K2300/00
摘要： Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
摘要翻译：本文提供了通过施用胰岛淀粉样多肽激动剂化合物治疗哺乳动物雌激素缺乏症的方法。本文还提供了在雌激素缺乏的哺乳动物中治疗肥胖和超重的方法; 在雌激素缺乏的哺乳动物中减少或维持体重和/或体内脂肪的方法; 以及通过施用有效量的胰淀素激动剂化合物来增加哺乳动物中Bdnf水平的方法。雌激素缺乏可能是由更年期，绝经前期，绝经后，卵巢功能障碍，过度切除术，子宫切除术等引起的。胰淀素激动剂化合物可以是本领域已知的或本文所述的任何一种，例如普兰林肽，达维兰苷或SEQ ID NO：142。

3. 发明申请

US20160102126A1 Novel Peptides Involved in Energy Homeostasis 审中-公开
标题翻译：涉及能量稳态的新型肽
公开(公告)号：US20160102126A1
公开(公告)日：2016-04-14
申请号：US14922557
申请日：2015-10-26
申请人： Andrew A. Butler , James L. Trevaskis
发明人： Andrew A. Butler , James L. Trevaskis
IPC分类号： C07K14/47 , A61K38/22 , A61K38/17
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice. Full-length ENHO1 peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Enho1”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠肥胖模型，KK-Ay和Lepob / Lepob小鼠中Enho1 mRNA的表达。通过腺病毒注射，Enho1的过度表达显着，并且可重复地降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Enho1蛋白的转基因小鼠品系。另外，通过在Lepob / Lepob小鼠中的ENHO1腺病毒治疗，参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达被降低。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长ENHO1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

4. 发明申请

US20100299769A1 NOVEL PEPTIDE INVOLVED IN ENERGY HOMEOSTASIS 有权
标题翻译：新能源参与能源管理
公开(公告)号：US20100299769A1
公开(公告)日：2010-11-25
申请号：US12848308
申请日：2010-08-02
申请人： Andrew A. Butler , James L. Trevaskis
发明人： Andrew A. Butler , James L. Trevaskis
IPC分类号： A01K67/00 , C07K14/00 , C07K7/08 , C07K14/47 , A61K38/16 , A61K38/10 , A61K38/22 , A61K31/7088 , C07K16/18 , C07H21/04 , A61P3/00 , A61P3/04 , C12N15/63 , C12N5/10 , C12N1/21 , C12N1/19 , C12P21/06
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice. Full-length ENHO1 peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Enho1”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠肥胖模型，KK-Ay和Lepob / Lepob小鼠中Enho1 mRNA的表达。通过腺病毒注射，Enho1的过度表达显着，并且可重复地降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Enho1蛋白的转基因小鼠品系。另外，通过在Lepob / Lepob小鼠中的ENHO1腺病毒治疗，参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达被降低。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长ENHO1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

5. 发明授权

US08518892B2 Methods to treat symptoms of pathophysiology related to body mass 有权
标题翻译：治疗与身体质量相关的病理生理学症状的方法
公开(公告)号：US08518892B2
公开(公告)日：2013-08-27
申请号：US12848308
申请日：2010-08-02
申请人： Andrew A. Butler , James L. Trevaskis
发明人： Andrew A. Butler , James L. Trevaskis
IPC分类号： A61K38/00 , A61K38/17 , A61K38/18
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice. Full-length ENHO1 peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Enho1”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠肥胖模型，KK-Ay和Lepob / Lepob小鼠中Enho1 mRNA的表达。通过腺病毒注射，Enho1的过度表达显着，并且可重复地降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Enho1蛋白的转基因小鼠品系。另外，通过在Lepob / Lepob小鼠中的ENHO1腺病毒治疗，参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达被降低。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长ENHO1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

6. 发明申请

US20090253619A1 Novel peptide involved in energy homeostasis 审中-公开
标题翻译：涉及能量稳态的新型肽
公开(公告)号：US20090253619A1
公开(公告)日：2009-10-08
申请号：US12012627
申请日：2008-02-05
申请人： Andrew A. Butler , James L. Trevaskis
发明人： Andrew A. Butler , James L. Trevaskis
IPC分类号： A61K38/16 , C07K14/435 , C07K14/00 , C07K7/08 , A61K38/10 , A61P3/04 , A61K38/22 , C12N15/63 , C12N1/20 , C12N1/16 , C12N5/06 , C12N5/04 , C12P21/00 , A61K31/7088 , C07K16/18 , A01K67/00 , A01K67/027
CPC分类号： C07K14/47 , A61K38/1709 , A61K38/22 , A61K38/2264 , C07K14/4702 , C07K16/18 , G01N33/68
摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice. Full-length ENHO1 peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.
摘要翻译：发现编码推定的76个氨基酸的分泌蛋白（“Enho1”）的mRNA的表达与空腹甘油三酯和胆固醇水平呈负相关。使用重组腺病毒增加两种小鼠肥胖模型，KK-Ay和Lepob / Lepob小鼠中Enho1 mRNA的表达。通过腺病毒注射，Enho1的过度表达显着，并且可重复地降低了两种模型中的空腹甘油三酯和胆固醇水平。此外，制备过表达Enho1蛋白的转基因小鼠品系。另外，通过在Lepob / Lepob小鼠中的ENHO1腺病毒治疗，参与脂肪生成（脂肪酸合酶）和FAS蛋白水平的关键基因的表达被降低。通过口服摄入，注射，皮下贴片或鼻内途径递送的全长ENHO1肽或其衍生物，同系物，类似物或模拟物可用作高胆固醇血症，高甘油三酯血症，胰岛素抵抗，肥胖症，糖尿病和/或能量失衡。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式